Bristol-Myers Squibb Company (BMY) shares are trading at lower $62.22 and the avg recommendation for the stock is Strong Buy. while the current analyst price target stands at $73.25.
To add more color to this target, the company’s high over the last year is $68.34 and the low is $45.76. Over the last 52 weeks, BMY is down -8.96% while the S&P 500 is up 0.31%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, BMY reported a profit of $7.43 billion. Bristol-Myers Squibb Company also saw revenues increase to $10.13 billion. In addition, BMY has free cash flow of $7.85 billion as of 06-2020. The company’s EBITDA came in at $4.18 billion which compares well with its peers.
BMY booked profit margins of -1.60%, its Return on Equity (ROE) is -1.30%, and its Return on Assets is -0.50%. All told, it is clear that, BMY needs to be on your watchlist.
Find out when BMY reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. BMY has a short ratio of 1.59 and outstanding shares of 2.26B.
BMY has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 8.65 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -0.10. Bristol-Myers Squibb Company BMY also noted assets of $128.08 billion at the end of the last quarter. Investors should also keep an eye on sector updates as BMY has historically followed its peers on positive news.
All told, Bristol-Myers Squibb Company BMY has strung together solid data and demonstrated underlying fundamentals. At its current valuation, BMY represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Bristol-Myers Squibb Company BMY is now commanding a market cap of 140.42B and a float of 2.25B. BMY is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of BMY stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in BMY, either long or short, and we have not been compensated for this article.